{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:16:55Z","timestamp":1793755015545,"version":"4.6.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1111\/j.1538-7836.2005.01368.x","type":"journal-article","created":{"date-parts":[[2005,8,8]],"date-time":"2005-08-08T04:34:38Z","timestamp":1123475678000},"page":"1628-1637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Medical management of peripheral arterial disease"],"prefix":"10.1016","volume":"3","author":[{"given":"B.L.W.","family":"BENDERMACHER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"WILLIGENDAEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.W.","family":"TEIJINK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"PRINS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0010","first-page":"2851","article-title":"Prevalentie van perifere arteri\u00eble vaatziekte en claudicatio intermittens bij personen van 55 jaar en ouder: het ERGO\u2010onderzoek","volume":"142","author":"Rutgers","year":"1998","journal-title":"NTVG"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/aje\/153.7.666","article-title":"Incidence of and risk factors for asymptomatic peripheral arterial disease: a longitudinal study","volume":"153","author":"Hooi","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/ije\/25.2.282","article-title":"The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease","volume":"25","author":"Stoffers","year":"1996","journal-title":"Int J Epidemiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archinte.159.4.387","article-title":"Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease","volume":"159","author":"McDermott","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1532-5415.1985.tb02853.x","article-title":"Update on some epidemiological features of intermittent claudication","volume":"33","author":"Kannel","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0035","first-page":"49","article-title":"The prognosis of non\u2010critical limb ischaemia: a systemic preview of population\u2010based evidence","volume":"49","author":"Hooi","year":"1999","journal-title":"Br J Gen Prac"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0040","first-page":"11","article-title":"Epidemiology of critical limb ischemia: north Italian data","volume":"2","author":"Catalano","year":"1993","journal-title":"Eur J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0045","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/bjs.1800811111","article-title":"Epidemiology of leg amputation: the influence of vascular surgery","volume":"81","author":"Ebskov","year":"1994","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0050","first-page":"S1","article-title":"Management of peripheral arterial disease. TASC Working Group. TransAtlantic Inter\u2010Society Consensus (TASC)","volume":"31","author":"Dormandy","year":"2000","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0055","first-page":"123","article-title":"The natural history of claudication: risk to life and limb","volume":"12","author":"Dormandy","year":"1999","journal-title":"Semin Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0060","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1067\/mva.2001.119749","article-title":"Natural history of claudication: long\u2010term serial follow\u2010up study of 1244 claudicants","volume":"34","author":"Aquino","year":"2001","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0272989X0202200208","article-title":"Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle\u2010brachial pressure index","volume":"22","author":"Hooi","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/000331979504600304","article-title":"Ankle\/arm pressure index in asymptomatic middle\u2010aged males: an independent predictor of ten\u2010year coronary heart disease mortality","volume":"46","author":"Kornitzer","year":"1995","journal-title":"Angiology"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0075","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/ije\/25.6.1172","article-title":"Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population","volume":"25","author":"Leng","year":"1996","journal-title":"Int J Epidemiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0080","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jvs.2004.08.049","article-title":"Influence of smoking on incidence and prevalence of peripheral arterial disease","volume":"40","author":"Willigendael","year":"2004","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0085","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/bjs.1800691309","article-title":"The measured effect of stopping smoking on intermittent claudication","volume":"69","author":"Quick","year":"1982","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.0954-6820.1987.tb00891.x","article-title":"Cessation of smoking in patients with intermittent claudication","volume":"221","author":"Jonason","year":"1987","journal-title":"Acta Med Scand"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0095","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archinte.159.4.337","article-title":"Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta\u2010analysis","volume":"159","author":"Girolami","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1358863X9700200314","article-title":"The role of tobacco cessation, antiplatelet and lipid\u2010lowering therapies in the treatment of peripheral arterial disease","volume":"2","author":"Hirsch","year":"1997","journal-title":"Vasc Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0105","series-title":"Treating Tobacco Use and Dependence","author":"Fiore","year":"2000"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0110","series-title":"Individual Behavioural Counselling for Smoking Cessation","author":"Lancaster","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0115","series-title":"Group Behaviour Therapy Programmes for Smoking Cessation","author":"Stead","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0120","first-page":"31","article-title":"Unsuccessful outpatient counselling to help patients with peripheral vascular disease to stop smoking","volume":"74","author":"Power","year":"1992","journal-title":"Ann Royal Coll Surg Eng"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0125","first-page":"525","article-title":"Management of peripheral arterial disease","volume":"69","author":"Gey","year":"2004","journal-title":"Am Fam Phys"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0130","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1001\/jama.1994.03510480064036","article-title":"The effectiveness of the nicotine patch for smoking cessation: a meta\u2010analysis","volume":"271","author":"Fiore","year":"1994","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0135","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2105\/AJPH.89.11.1701","article-title":"Over\u2010the\u2010counter nicotine patch therapy for smoking cessation: results from a randomized, double\u2010blind, placebo\u2010controlled, and open label trials","volume":"89","author":"Hays","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0140","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM199612123352402","article-title":"The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease","volume":"335","author":"Joseph","year":"1996","journal-title":"New Eng J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0145","author":"Silagy","year":"2004","journal-title":"Nicotine Replacement Therapy for Smoking Cessation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0150","series-title":"NICE a Rapid and Systematic Review of the Clinical and Cost Effectiveness of Bupropion SR and Nicotine Replacement Therapy (NRT) for Smoking Cessation","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199903043400903","article-title":"A controlled trial of sustained\u2010release bupropion, a nicotine patch, or both for smoking cessation","volume":"340","author":"Jorenby","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0160","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2165\/00003495-200059040-00019","article-title":"Bupropion: a review of its use in the management of smoking cessation","volume":"59","author":"Holm","year":"2000","journal-title":"Drugs"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003495-200262002-00004","article-title":"Use of sustained\u2010release bupropion in specific patient populations for smoking cessation","volume":"62","author":"Tonstad","year":"2002","journal-title":"Drugs"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0170","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199710233371703","article-title":"A comparison of sustained\u2010release bupropion and placebo for smoking cessation","volume":"337","author":"Hurt","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1078-5884(03)00356-3","article-title":"Smoking cessation strategies in patients with peripheral arterial disease: an evidence\u2010based approach","volume":"26","author":"Hobbs","year":"2003","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0180","series-title":"Hypnotherapy for Smoking Cessation","author":"Abbot","year":"1998"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0185","series-title":"Aversive Smoking for Smoking Cessation","author":"Hajek","year":"2004"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0190","series-title":"Cochrane Database Syst Rev","article-title":"Acupuncture for smoking cessation","author":"White","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0195","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1056\/NEJMcp012279","article-title":"Clinical practice. Treatment of tobacco use and dependence","volume":"346","author":"Rigotti","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0200","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2796.1990.tb00176.x","article-title":"The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non\u2010randomized controlled study","volume":"227","author":"Olsson","year":"1990","journal-title":"J Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0205","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(83)92527-8","article-title":"Treatment of hyperlipidemia retards progression on symptomatic femoral atherosclerosis: a randomised controlled trial","volume":"2","author":"Duffield","year":"1983","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial Results. I: Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0215","doi-asserted-by":"crossref","first-page":"40C","DOI":"10.1016\/S0002-9149(99)80469-X","article-title":"Effect of parvastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries; a report for the Regression Growth Evaluation Statin Study","volume":"76","author":"De Groot","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatine in 20,536 high\u2010risk individuals: a randomised placebo\u2010controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)","volume":"81","author":"Pedersen","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9149(03)00833-6","article-title":"Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment","volume":"92","author":"Aronow","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0235","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0240","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.CIR.0000050380.64025.07","article-title":"Statin use and leg functioning in patients with and without lower\u2010extremity peripheral arterial disease","volume":"107","author":"McDermott","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0245","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","article-title":"Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease","volume":"114","author":"Mondillo","year":"2003","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0250","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0255","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long\u2010term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0260","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0265","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0270","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/01.ATV.18.12.1942","article-title":"Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication","volume":"18","author":"Elam","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0275","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0280","first-page":"18","article-title":"Pharmacotherapy and behavioural interventions for peripheral arterial disease","volume":"4","author":"Doyle","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0285","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/15.suppl_C.2","article-title":"Peripheral vascular effects of beta\u2010blockers","volume":"15","author":"Heintzen","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0290","article-title":"Treatment of hypertension in peripheral arterial disease (Cochrane Review)","volume":"2","author":"Lip","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0295","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/000331979204300905","article-title":"Double\u2010blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication","volume":"43","author":"Roberts","year":"1992","journal-title":"Angiology"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0300","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(87)92441-X","article-title":"Placebo\u2010controlled comparison of captopril, atenolol, labetolol, and pindolol in hypertension complicated by intermittent claudication","volume":"ii","author":"Roberts","year":"1987","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0305","first-page":"169","article-title":"Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication","volume":"15","author":"Novo","year":"1996","journal-title":"Int Angiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0310","first-page":"357","article-title":"The influence of chronic treatment with betablockade and converting enzyme inhibition on peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication","volume":"23","author":"Ven van de","year":"1994","journal-title":"Vasa"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.1972.03200200011003","article-title":"Presiposition to atherosclerosis in the head, heart, and legs: the Framingham study","volume":"221","author":"Gordon","year":"1972","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/oxfordjournals.aje.a116294","article-title":"Smoking, lipids, glucose in\u2010tolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study","volume":"135","author":"Fowkes","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0325","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long\u2010term complication in insulin\u2010dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0330","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/diacare.25.5.894","article-title":"UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes","volume":"25","author":"Adler","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0335","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","article-title":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications trial","volume":"75","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0340","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.322.7277.15","article-title":"Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC\u2010Norfolk)","volume":"322","author":"Khaw","year":"2001","journal-title":"Br Med J"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0350","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJM199104253241701","article-title":"Hyperhomocysteinemia: an independent risk factor for vascular disease","volume":"324","author":"Clarke","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0355","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.1997.03540460039030","article-title":"Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project","volume":"277","author":"Graham","year":"1997","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0360","article-title":"Homocysteine lowering interventions for peripheral arterial disease and bypass grafts","volume":"3","author":"Hansrani","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(89)90200-1","article-title":"Reduction of plasma lipid and homocysteine levels by pyridoxine, folate cobalamin, choline, riboflavin, and troxerutin in atherosclerosis","volume":"75","author":"Olszewski","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0370","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0026-0495(88)90093-5","article-title":"Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease","volume":"37","author":"Wilcken","year":"1998","journal-title":"Metabolism"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0375","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","article-title":"Medical treatment of peripheral arterial disease and claudication","volume":"344","author":"Hiatt","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0380","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1046\/j.0007-1323.2001.01774.x","article-title":"Systemic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease","volume":"88","author":"Robless","year":"2001","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0385","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta\u2010analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0390","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.292.15.1867","article-title":"Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease","volume":"292","author":"Tran","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0395","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0140-6736(92)93216-A","article-title":"Low\u2010dose aspirin and subsequent peripheral arterial surgery in the Physician's Health Study","volume":"340","author":"Goldhaber","year":"1992","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0400","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0405","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.0007-1323.2001.01971.x","article-title":"Aspirin resistance","volume":"89","author":"Smout","year":"2002","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0410","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0415","series-title":"Thienopyridine Derivatives (Ticlopidine, Clopidogrel) Versus Aspirin for Preventing Stroke and other Serious Vascular Events in High Vascular Risk Patients","author":"Hankey","year":"1999"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0420","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ejvs.2002.1927","article-title":"Antiplatelet therapy in peripheral arterial disease. Consensus statement","volume":"26","year":"2003","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0430","doi-asserted-by":"crossref","DOI":"10.3310\/hta8380","article-title":"Clinical effectiveness and cost\u2010effectiveness of clopidogrel and modified\u2010release dipyridamole in the secondary prevention of occlusive vascular events: a systemic review and economic evaluation. Executive Summary","volume":"8","author":"Jones","year":"2004","journal-title":"Health Techn Assess"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0435","series-title":"Physicians\u2019 Desk Reference","article-title":"PDR\u00ae entry for Plavix tablets (Sanofi\u2010Synthelabo)","year":"2001"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0440","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0741-5214(03)01029-2","article-title":"Managing peripheral arterial disease with multiple platelet inhibitors: the effect of combination therapy on bleeding time","volume":"38","author":"Wilhite","year":"2003","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0445","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease (Cochrane Review)","volume":"2","author":"De Schryver","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0450","series-title":"The Cochrane Database of Systemic Reviews","article-title":"Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication (Cochrane Review)","author":"Cosmi","year":"2000"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0455","series-title":"The Cochrane Database of Systemic Reviews","article-title":"Exercise for intermittent claudication (Cochrane Review)","author":"Leng","year":"2000"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0460","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0741-5214(97)70352-5","article-title":"Value of a supervised exercise program for the therapy of arterial claudication","volume":"25","author":"Patterson","year":"1997","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0465","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejvs.2003.09.012","article-title":"Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomised trial","volume":"27","author":"Cheetham","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0470","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jama.1995.03530120067043","article-title":"Exercise rehabilitation programs for the treatment of claudication pain \u2013 a meta\u2010analysis","volume":"274","author":"Gardner","year":"1995","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0475","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra021135","article-title":"Exercise training for claudication","volume":"347","author":"Stewart","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0480","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.CIR.99.7.963","article-title":"Exercise as cardiovascular therapy","volume":"99","author":"Shephard","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0485","first-page":"1053","article-title":"Management of intermittent claudication with pentoxifylline: a meta\u2010analysis of randomized controlled trials","volume":"155","author":"Hood","year":"1996","journal-title":"CMAJ"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0490","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/000331979404500502","article-title":"Pentoxifylline for intermittent claudication: a critical review","volume":"45","author":"Ernst","year":"1994","journal-title":"Angiology"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0495","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-113-2-135","article-title":"Conservative management of intermittent claudication","volume":"113","author":"Radack","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0500","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-8703(82)90642-1","article-title":"Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double\u2010blind trial with objective assessment of chronic occlusive arterial disease patients","volume":"104","author":"Porter","year":"1982","journal-title":"Am Heart J"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0505","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1445-5994.1985.tb02759.x","article-title":"Intermittent claudication: a double\u2010blind crossover trial of pentoxifylline","volume":"5","author":"Gallus","year":"1985","journal-title":"Aust NZ J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0510","first-page":"445","article-title":"A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects","volume":"100","author":"Reilly","year":"1987","journal-title":"NZ Med J"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0515","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9343(00)00569-6","article-title":"A comparison of cilostazol and pentoxifylline for treating intermittent claudication","volume":"109","author":"Dawson","year":"2000","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0520","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.CIR.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double\u2010blind trial","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0525","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0741-5214(98)70357-X","article-title":"Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease","volume":"27","author":"Money","year":"1998","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0530","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/archinte.159.17.2041","article-title":"A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial","volume":"159","author":"Beebe","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0535","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1046\/j.1532-5415.2002.50604.x","article-title":"Effect of cilostazol on treadmill walking, community\u2010based walking ability, and health\u2010related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta\u2010analysis of six randomized controlled trials","volume":"50","author":"Regensteiner","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0540","series-title":"Pletal (package insert)","year":"1999"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0545","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1024\/0301-1526.28.3.207","article-title":"Naftidrofuryl can enhance the quality of life in patients with intermittent claudication","volume":"28","author":"Spengel","year":"1999","journal-title":"VASA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0550","first-page":"58","article-title":"A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS)","volume":"20","author":"Kieffer","year":"2001","journal-title":"Int Angiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0555","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00005344-199000163-00019","article-title":"The effect of naftidrofuryl on intermittent claudication: a meta\u2010analysis","volume":"16","author":"Lehert","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0560","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/000331978403501103","article-title":"Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study","volume":"35","author":"Tr\u00fcbestein","year":"1994","journal-title":"Angiology"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0565","first-page":"20","article-title":"Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program","volume":"21","author":"Spengel","year":"2002","journal-title":"Int Angiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0570","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5414\/CPP42063","article-title":"Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD) \u2013 a review based on randomized, controlled studies","volume":"42","author":"Horsch","year":"2004","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0575","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0002-9343(99)00454-4","article-title":"Ginkgo biloba extract for the treatment of intermittent claudication: a meta\u2010analysis of randomized trials","volume":"108","author":"Pittler","year":"2000","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0580","first-page":"107","article-title":"Pr\u00fcfrichtlinien f\u00fcr Therapiestudien im Fontaine\u2010Stadium II\u2010IV bei peripherer arterieller Verschlusskrankheit","volume":"24","author":"Heidrich","year":"1995","journal-title":"VASA"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0585","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0735-1097(99)00373-3","article-title":"European multicenter study on propionyl\u2010l\u2010carnitine in intermittent claudication","volume":"34","author":"Brevetti","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0590","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/039139880402700107","article-title":"Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: an oxygen\u2010controlled study","volume":"27","author":"Biedunkiewicz","year":"2004","journal-title":"Int J Artif Organs"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0595","series-title":"Chelation Therapy for Atherosclerotic Cardiovascular Disease","author":"Villaruz","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0600","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10623320390246414","article-title":"Vascular endothelial growth factor response in porcine coronary and peripheral arteries using nonsurgical occlusion model, local delivery, and liposome\u2010mediated gene transfer","volume":"10","author":"Pelisek","year":"2003","journal-title":"Endothelium"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0605","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jgm.594","article-title":"Human FGF\u20101 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters","volume":"6","author":"Caron","year":"2004","journal-title":"J Gene Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0610","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(85)91144-4","article-title":"Drug\u2010induced inhibition of platelet function delays progression in peripheral occlusive arterial disease: a prospective double\u2010blind arteriographically controlled trial","volume":"1","author":"Hess","year":"1985","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0615","series-title":"Fraxiparine. Analytic and Structural Data, Pharmacology, Clinical Trials","first-page":"21","article-title":"Efficacy and safety of CY216 in the treatment of specific leg ulcers","author":"Gauthier","year":"1987"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0620","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.CIR.97.12.1114","article-title":"Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia","volume":"97","author":"Baumgartner","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0625","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(02)09670-8","article-title":"Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone\u2010marrow cells: a pilot study and a randomised controlled trial","volume":"360","author":"Tateishi\u2010Yuyama","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0630","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0002-9343(02)01392-X","article-title":"Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia","volume":"114","author":"Shyu","year":"2003","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0635","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(02)08937-7","article-title":"Therapeutic angiogenesis with recombinant fibroblast growth factor\u20102 for intermittent claudication (TRAFFIC study)","volume":"359","author":"Lederman","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2004.03.021","article-title":"Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?","volume":"28","author":"Collinson","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0645","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/bjs.4629","article-title":"Systemic review and meta\u2010analysis of controlled trials assessing spinal cord stimulation for inoperable critical leg ischemia","volume":"91","author":"Ubbink","year":"2004","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0650","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/ejvs.1999.0975","article-title":"A systematic review of intra\u2010arterial thrombolytic therapy for lower\u2010limb ischemia","volume":"19","author":"Palfrayman","year":"2000","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0655","series-title":"Surgery Versus Thrombolysis for Initial Management of Acute Limb Ischemia","author":"Berridge","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0660","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00000658-199409000-00003","article-title":"Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial","volume":"220","year":"1994","journal-title":"Ann Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0665","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1067\/mva.2003.41","article-title":"The safety, efficacy, and pharmacoeconomics of low\u2010dose alteplase compared with urokinase for catheter\u2010directed thrombolysis of arterial and venous occlusions","volume":"37","author":"Sugimoto","year":"2003","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0670","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/01.RVI.0000079981.80153.02","article-title":"Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: a pilot study","volume":"14","author":"Burkart","year":"2003","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0675","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","article-title":"Mechanisms of disease: platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine","volume":"332","author":"Lefkovits","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0680","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/000331970005101104","article-title":"Short\u2010 and long\u2010term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis","volume":"51","author":"Schweizer","year":"2000","journal-title":"Angiology"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0685","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long\u2010term treatment with a platelet glycoprotein\u2010receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events","volume":"342","author":"O'Neill","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0690","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","article-title":"Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS\u2010TIMI 16) trial","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01368.x_bb0695","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1148\/radiol.2213010400","article-title":"Peripheral artery occlusion: treatment with abciximab plus urokinase versus urokinase alone: a randomized pilot trial (the PROMPT study)","volume":"221","author":"Duda","year":"2001","journal-title":"Radiology"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2005.01368.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622162987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622162987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2005.01368.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:38:21Z","timestamp":1761532701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622162987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":138,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S1538783622162987"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01368.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical management of peripheral arterial disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01368.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}